Baseline patient characteristics of primary common support sets for response and survival
| Characteristics . | Common support set for response . | Common support set for survival . | ||
|---|---|---|---|---|
| ZUMA-1 (N = 80) . | SCHOLAR-1 (N = 340) . | ZUMA-1 (N = 81) . | SCHOLAR-1 (N = 331) . | |
| Male sex | 53 (66) | 231 (68) | 54 (67) | 225 (68) |
| Age ≥65 y | 19 (24) | 56 (16) | 19 (23) | 51 (15) |
| ≥3 lines of chemotherapy and ASCT* | 49 (61) | 98 (29) | 50 (62) | 93 (28) |
| Ever primary refractory† | 23 (29) | 126 (37) | 23 (28) | 125 (38) |
| Refractory to ≥2 consecutive lines of therapy | 43 (54) | 170 (50) | 43 (53) | 165 (50) |
| SCT any time after refractory disease | 14 (18) | 126 (37) | 14 (17) | 125 (38) |
| Relapse within 12 mo of ASCT | 16 (20) | 74 (22) | 16 (20) | 71 (21) |
| ECOG PS 0-1‡ | 80 (100) | 126/126 (100)§ | 81 (100) | 126/126 (100)§ |
| Disease stage III-IV‡ | 67 (84) | 80/124 (65)§ | 68 (84) | 80/124 (65)§ |
| IPI score ≥3‡ | 34 (43) | 33/119 (28)§ | 35 (43) | 33/119 (28)§ |
| Characteristics . | Common support set for response . | Common support set for survival . | ||
|---|---|---|---|---|
| ZUMA-1 (N = 80) . | SCHOLAR-1 (N = 340) . | ZUMA-1 (N = 81) . | SCHOLAR-1 (N = 331) . | |
| Male sex | 53 (66) | 231 (68) | 54 (67) | 225 (68) |
| Age ≥65 y | 19 (24) | 56 (16) | 19 (23) | 51 (15) |
| ≥3 lines of chemotherapy and ASCT* | 49 (61) | 98 (29) | 50 (62) | 93 (28) |
| Ever primary refractory† | 23 (29) | 126 (37) | 23 (28) | 125 (38) |
| Refractory to ≥2 consecutive lines of therapy | 43 (54) | 170 (50) | 43 (53) | 165 (50) |
| SCT any time after refractory disease | 14 (18) | 126 (37) | 14 (17) | 125 (38) |
| Relapse within 12 mo of ASCT | 16 (20) | 74 (22) | 16 (20) | 71 (21) |
| ECOG PS 0-1‡ | 80 (100) | 126/126 (100)§ | 81 (100) | 126/126 (100)§ |
| Disease stage III-IV‡ | 67 (84) | 80/124 (65)§ | 68 (84) | 80/124 (65)§ |
| IPI score ≥3‡ | 34 (43) | 33/119 (28)§ | 35 (43) | 33/119 (28)§ |
Unless otherwise noted, data are n (%).
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
Either prior to ZUMA-1 or prior to and including the qualifying line of therapy (ie, the next-to-last treatment a SCHOLAR-1 patient received that was used to determine the most recent refractory status) in SCHOLAR-1.
Refractory to initial therapy; patients may or may not have been refractory to subsequent therapies.
Assessed at baseline for ZUMA-1 and within 3 months of determination of refractory status and prior to salvage therapy in SCHOLAR-1. Disease stage, IPI score, and ECOG PS were not available for all SCHOLAR-1 patients.
Data are n/N (%).